Moderna CEO Reveals His Massive Plans for Cancer, AI & Beyond!!
If you’re looking for more AI stock ideas, check out our new AGI service.
http://agi.fool.com
Moderna (MRNA) suffered a staggering 95% stock price decline from its pandemic-era highs. But CEO Stephane Bancel believes Wall Street still underestimates the company’s mRNA platform. In this conversation with Motley Fool co-founder Tom Gardner, Bancel discusses five approved vaccines, personalized cancer treatments, AI-driven drug development, and why he continues investing for the next decade. Is Moderna’s biggest opportunity still ahead, or do its clinical and commercial risks justify caution?
————————————————————————
This video is brought to you by The Motley Fool.
Visit https://fool.com/Invest to get access to this special offer. The Motley Fool Stock Advisor returns are 927% as of 8/5/2026 and measured against the S&P 500 returns of 211% as of 8/5/2026. Past performance is not an indicator of future results. All investing involves a risk of loss. Individual investment results may vary, not all Motley Fool Stock Advisor picks have performed as well.
If you want market-beating stock picks from our analysts, check out https://www.fool.com/epic-50
